JP2017525712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525712A5 JP2017525712A5 JP2017510539A JP2017510539A JP2017525712A5 JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5 JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- contained
- range
- tablet according
- azepino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007884 disintegrant Substances 0.000 claims description 16
- 239000000945 filler Substances 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 10
- JBXRLVPILRXPNH-UHFFFAOYSA-N indol-6-one Chemical compound O=C1C=CC2=CC=NC2=C1 JBXRLVPILRXPNH-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 5
- FUYPZKGDKZUPPC-UHFFFAOYSA-N 3,10-diazatricyclo[6.4.1.04,13]trideca-1(12),2,4,6,8(13),10-hexaen-9-one Chemical compound O=C1N=CC=C2C=NC3=CC=CC1=C23 FUYPZKGDKZUPPC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US62/040,849 | 2014-08-22 | ||
| US201562101739P | 2015-01-09 | 2015-01-09 | |
| US62/101,739 | 2015-01-09 | ||
| PCT/US2015/045522 WO2016028689A1 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149084A Division JP6797980B2 (ja) | 2014-08-22 | 2019-08-15 | ルカパリブの高投与力価錠剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525712A JP2017525712A (ja) | 2017-09-07 |
| JP2017525712A5 true JP2017525712A5 (enExample) | 2018-09-27 |
| JP6574477B2 JP6574477B2 (ja) | 2019-09-11 |
Family
ID=55347324
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510539A Active JP6574477B2 (ja) | 2014-08-22 | 2015-08-17 | ルカパリブの高投与力価錠剤 |
| JP2019149084A Active JP6797980B2 (ja) | 2014-08-22 | 2019-08-15 | ルカパリブの高投与力価錠剤 |
| JP2020191356A Active JP7127101B2 (ja) | 2014-08-22 | 2020-11-18 | ルカパリブの高投与力価錠剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149084A Active JP6797980B2 (ja) | 2014-08-22 | 2019-08-15 | ルカパリブの高投与力価錠剤 |
| JP2020191356A Active JP7127101B2 (ja) | 2014-08-22 | 2020-11-18 | ルカパリブの高投与力価錠剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (enExample) |
| EP (1) | EP3182975B1 (enExample) |
| JP (3) | JP6574477B2 (enExample) |
| KR (2) | KR20170043597A (enExample) |
| CN (2) | CN113209033A (enExample) |
| AU (2) | AU2015305696B2 (enExample) |
| BR (1) | BR112017000865A2 (enExample) |
| CA (1) | CA2955495C (enExample) |
| DK (1) | DK3182975T3 (enExample) |
| ES (1) | ES3048688T3 (enExample) |
| FI (1) | FI3182975T3 (enExample) |
| HR (1) | HRP20251484T1 (enExample) |
| IL (1) | IL249946B (enExample) |
| LT (1) | LT3182975T (enExample) |
| MX (1) | MX367260B (enExample) |
| NZ (1) | NZ728392A (enExample) |
| PT (1) | PT3182975T (enExample) |
| RS (1) | RS67356B1 (enExample) |
| RU (1) | RU2705156C2 (enExample) |
| SG (1) | SG11201700265VA (enExample) |
| SI (1) | SI3182975T1 (enExample) |
| WO (1) | WO2016028689A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383378B (es) | 2014-02-05 | 2025-03-13 | Merck Sharp & Dohme Llc | Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina. |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| ES3048688T3 (en) | 2014-08-22 | 2025-12-11 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| JP7269227B2 (ja) | 2017-09-26 | 2023-05-08 | テサロ， インコーポレイテッド | ニラパリブ処方物 |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| BR112020013672A2 (pt) | 2018-01-05 | 2020-12-01 | Cybrexa 1, Inc. | compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| CN111542527A (zh) * | 2018-12-06 | 2020-08-14 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| BR112022000337A2 (pt) | 2019-07-10 | 2022-04-12 | Cybrexa 2 Inc | Conjugados de peptídeos de citotoxinas como terapêuticos |
| AU2020311925A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2021220120A1 (en) | 2020-04-28 | 2021-11-04 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| HRP20251324T1 (hr) | 2020-07-14 | 2025-12-05 | Assia Chemical Industries Ltd. | Oblici soli rukapariba u krutom stanju |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| EP4429636A1 (en) * | 2021-11-10 | 2024-09-18 | Crititech, Inc. | Rucaparib particles and uses thereof |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360003C (en) | 1999-01-11 | 2012-07-10 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ES2339663T3 (es) | 2003-07-25 | 2010-05-24 | Cancer Research Technology Limited | Inhibidores de parp triciclicos. |
| JP4966858B2 (ja) | 2004-09-22 | 2012-07-04 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害薬の製造方法 |
| ES2382950T3 (es) | 2004-09-22 | 2012-06-14 | Pfizer, Inc. | Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona |
| NZ553295A (en) | 2004-09-22 | 2010-04-30 | Pfizer | Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor |
| CA2720744A1 (en) * | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| PL2534153T5 (pl) | 2010-02-12 | 2024-11-18 | Pfizer Inc. | Sole i polimorfy 8-fluoro-2-{4-[(metyloamino}metylo]fenylo}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-onu |
| AU2013243291B2 (en) | 2012-04-05 | 2018-02-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
| ES3048688T3 (en) | 2014-08-22 | 2025-12-11 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
-
2015
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 HR HRP20251484TT patent/HRP20251484T1/hr unknown
- 2015-08-17 SI SI201532081T patent/SI3182975T1/sl unknown
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525712A5 (enExample) | ||
| RU2017109139A (ru) | Таблетки, содержащие большую дозу рукапариба | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| JP7023945B2 (ja) | レナリドミドの経口用錠剤組成物 | |
| JP6245677B2 (ja) | 口腔内崩壊錠 | |
| JP2011098964A5 (enExample) | ||
| ES2311442T1 (es) | Dosis en forma oral. | |
| EP3041511A2 (en) | Compositions of eltrombopag | |
| WO2015071432A1 (en) | Pharmaceutical compositions of ibrutinib | |
| JP2015521191A5 (enExample) | ||
| CN101478966B (zh) | 压缩制剂 | |
| CA2764172A1 (en) | A thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| JP2005538097A (ja) | Ｈｍｇ−ｃｏａレダクターゼインヒビターを含む組成物 | |
| CN101312714A (zh) | 替米沙坦的药用组合物 | |
| KR20180083239A (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
| CA2833115C (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| WO2014058047A1 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| JP2019532960A (ja) | エソメプラゾール含有複合カプセル剤及びその製造方法 | |
| WO2011080706A1 (en) | Enhanced solubility of ziprasidone | |
| KR20100083047A (ko) | 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물 | |
| WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
| JP2016539109A (ja) | イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法 | |
| JP5241511B2 (ja) | 溶出性の改善された医薬組成物 | |
| JP2007512287A5 (enExample) |